Skip to main content
. 2014 Feb 17;8:39. doi: 10.3389/fncel.2014.00039

Figure 3.

Figure 3

A functional D1R-PKA axis is necessary to permit the persistent activity-dependent increase in LP Ih Gmax. (A) Diagram of the experimental protocol. (B) The D1R inhibitor, flupenthixol (10 µM), had no effect on its own, but prevented the DA- and activity-dependent persistent increase in LP Ih Gmax. LP Ih Gmax is plotted for every treatment group; each symbol represents one experiment, and the horizontal bars represent the means. Asterisks indicate significant differences as determined using a one-way ANOVA with Tukey’s post hoc tests that made all pairwise comparisons: F(3,21) = 6.642, p = 0.0025. (C) The PKA inhibitor, Rp-cAMPS (1 mM), had no effect on its own, but prevented the DA- and activity-dependent persistent increase in LP Ih Gmax. Asterisks indicate significant differences as determined using a one-way ANOVA with Tukey’s multiple comparisons post hoc tests: F(3,24) = 5.9, p = 0.0036. (D) The PKA inhibitor, myristoylated PKI(14–22) (5 µM), prevented the DA- and activity-dependent persistent increase in LP Ih Gmax, but had no effect on its own. Asterisks indicate significant differences as determined using a one-way ANOVA with Tukey’s multiple comparisons post hoc tests: F(3,22) = 10.38, p = 0.0002.